TLDR Current treatments for androgenetic alopecia are limited, but research is ongoing to find better solutions.
The review article discusses the current and emerging treatments for androgenetic alopecia, the most common form of non-cicatricial hair loss, particularly affecting men. It highlights the limited number of treatments with proven efficacy approved by recognized organizations, prompting ongoing research to discover new drugs and improve existing therapies. The article reviews various treatment options, including minoxidil, 5a-reductase inhibitors (administered orally, topically, and by injection), tretinoin, botulinum toxin, microRNA, and osteopontin, as potential solutions for managing androgenetic alopecia.
145 citations,
November 2017 in “Journal of The European Academy of Dermatology and Venereology” Use minoxidil for hair loss treatment; assess results after 6 months.
[object Object] 
1 citations,
July 2018 in “Elsevier eBooks” Many treatments for hair loss show potential, but more testing is needed to confirm their effectiveness. Only minoxidil for women and minoxidil and finasteride for men are FDA approved.
23 citations,
January 2013 in “Indian Journal of Dermatology, Venereology and Leprology” FPHL causes hair loss in women due to genetics and hormones; minoxidil and anti-androgens are treatments, and early intervention is advised.
November 2020 in “Postepy Dermatologii I Alergologii” Sulfotransferase SULT1A1 activity may predict minoxidil treatment success for hair loss.
18 citations,
January 2013 in “Postepy Dermatologii I Alergologii” Puberty often causes skin issues like acne and excessive sweating, and treatments require patience as results may vary.
